| Literature DB >> 32709239 |
Karina Berner1, John Cockcroft2, Quinette Louw3.
Abstract
BACKGROUND: Inertial measurement unit (IMU)-based motion capture systems are gaining popularity for gait analysis outside laboratories. It is important to determine the performance of such systems in specific patient populations. We aimed to validate and determine within-day reliability of an IMU system for measuring lower limb gait kinematics and temporal-spatial parameters (TSP) in people with and without HIV.Entities:
Keywords: Gait analysis; HIV infection; Inertial measurement units; Inertial motion capture; Kinematics; Measurement error; Reliability; Temporospatial parameters; Validity
Mesh:
Year: 2020 PMID: 32709239 PMCID: PMC7379351 DOI: 10.1186/s12938-020-00802-2
Source DB: PubMed Journal: Biomed Eng Online ISSN: 1475-925X Impact factor: 2.819
Fig. 1Validity of gait parameters and kinematics measured by inertial measurement units (relative to optical motion capture). Error bars indicate 95% confidence intervals
Concurrent validity of gait parameters measured by inertial measurement units (relative to optical motion capture)
| Parameter | RMSE, mean (SD) | MAPE, % | Bias | LoA | RMSE, mean (SD) | MAPE, % | Bias | LoA |
|---|---|---|---|---|---|---|---|---|
| SNP | PLHIV | |||||||
| Spatial parameters | ||||||||
| Step length (cm) | 3.22 (1.63) | 1.66 | − 1.05 | − 5.83; 3.72 | 4.38 (2.01) | 1.07 | − 0.74 | − 4.95; 3.47 |
| Normalized step length | 0.04 (0.02) | 1.66 | − 0.01 | − 0.07; 0.04 | 0.05 (0.02) | 1.07 | − 0.01 | − 0.05; 0.04 |
| Stride length | 4.46 (3.51) | 2.51 | − 3.26 | − 11.45; 4.92 | 4.46 (2.62) | 2.28 | − 2.95 | − 10.68; 4.78 |
| Normalized stride length | 0.05 (0.04) | 2.51 | − 0.04 | − 0.13; 0.05 | 0.05 (0.03) | 2.28 | − 0.03 | − 0.11; 0.05 |
| Temporal parameters | ||||||||
| Cadence (steps/min) | 6.93 (4.41) | 0.39 | 0.49 | − 5.55; 6.54 | 6.15 (4.86) | 0.18 | 0.01 | − 4.75; 5.00 |
| Stance time (s) | 0.02 (0.01) | 1.22 | 0.01 | − 0.03; 0.04 | 0.03 (0.02) | 1.06 | 0.01 | − 0.04; 0.05 |
| Step time (s) | 0.03 (0.02) | 0.12 | < 0.00 | − 0.03; 0.03 | 0.03 (0.02) | 0.17 | < 0.00 | − 0.02; 0.02 |
| Single support time (s) | 0.02 (0.01) | 1.21 | − 0.01 | − 0.03; 0.02 | 0.02 (0.01) | 1.43 | − 0.01 | − 0.02; 0.01 |
| Double support time (s) | 0.03 (0.01) | 7.40 | 0.01 | − 0.04; 0.06 | 0.03 (0.03) | 5.79 | 0.01 | − 0.05; 0.07 |
| Temporophasic parameters | ||||||||
| Stance percentage (%GC) | 1.72 (0.39) | 0.98 | 0.57 | − 1.37; 2.51 | 1.97 (1.23) | 1.13 | 0.69 | − 2.00; 3.43 |
| Single support percentage (%GC) | 2.44 (1.35) | 1.37 | − 0.57 | − 3.53; 2.39 | 2.31 (1.40) | 1.26 | − 0.50 | − 3.24; 2.24 |
| Double support percentage (%GC) | 3.01 (1.14) | 6.96 | 1.14 | − 3.58; 5.86 | 2.68 (2.29) | 5.69 | 1.18 | − 4.14; 6.51 |
| Temporospatial parameters | ||||||||
| Gait speed (m/s) | 0.04 (0.03) | 2.68 | − 0.03 | − 0.11; 0.04 | 0.04 (0.03) | 2.13 | − 0.03 | − 0.10; 0.05 |
| Normalized gait speed | 0.01 (0.01) | 2.68 | − 0.01 | − 0.04; 0.01 | 0.01 (0.01) | 2.13 | − 0.01 | − 0.03; 0.02 |
MAPE mean absolute percentage error, GC gait cycle, LoA limits of agreement, PLHIV people living with HIV-1 infection, RMSE root-mean-square error, SNP HIV-seronegative participants
Concurrent validity of kinematic angles measured by inertial measurement units (relative to optical motion capture)
| Angle/ROM (degrees) | RMSE, mean (SD) | Bias | LoA | RMSE, mean (SD) | Bias | LoA |
|---|---|---|---|---|---|---|
| SNP | PLHIV | |||||
| Pelvis | ||||||
| Pelvis tilt ROM | 2.1 (1.1) | 2.0 | − 0.1; 4.1 | 2.9 (1.8) | 2.2 | − 2.2; 6.5 |
| Peak anterior pelvis tilt | 10.2 (7.1) | − 10.1 | − 24.4; 4.2 | 12.5 (5.9) | − 12.5 | − 24.2; − 0.8 |
| Pelvis obliquity ROM | 2.4 (1.7) | − 0.6 | − 6.2; 5.0 | 4.7 (3.3) | 1.7 | − 9.3; 12.7 |
| Pelvis rotation ROM | 3.3 (1.7) | 3.0 | − 0.6; 6.6 | 4.1 (2.4) | 3.7 | − 1.2; 8.6 |
| Pelvis rotation, IC | 5.5 (2.0) | 1.2 | − 1.0; 3.5 | 5.7 (4.5) | 2.2 | − 1.0; 5.5 |
| Hip | ||||||
| Hip flexion ROM | 3.5 (1.1) | − 3.1 | − 6.0; − 0.2 | 5.5 (2.1) | − 5.0 | − 9.1; − 1.0 |
| Hip flexion ROM, LR | 1.9 (1.5) | 0.5 | − 1.3; 2.3 | 2.3 (1.3) | 1.3 | − 2.0; 4.6 |
| Hip flexion ROM, PS to IS (H3) | 3.1 (1.4) | < 0.0 | − 5.2; 5.1 | 5.1 (4.4) | − 1.6 | − 10.4; 7.2 |
| Hip flexion, IC | 8.7 (5.1) | − 5.4 | − 22.0; 11.3 | 10.6 (4.5) | − 9.4 | − 22.1; 3.4 |
| Peak hip flexion, swing | 7.8 (4.8) | − 3.7 | − 20.1; 12.7 | 10.0 (4.4) | − 9.0 | − 21.0; 3.0 |
| Peak hip extension, stance | 7.3 (3.9) | 0.6 | − 16.0; 17.1 | 6.7 (3.7) | 4.0 | − 8.8; 16.7 |
| Hip abduction ROM, MSt | 3.2 (1.7) | < 0.0 | − 5.3; 5.4 | 4.5 (3.1) | 3.3 | − 3.1; 9.6 |
| Hip adduction ROM, LR | 3.2 (1.4) | 2.8 | − 0.1; 5.6 | 2.9 (1.9) | 2.5 | − 1.4; 6.3 |
| Hip internal rotation ROM | 5.2 (1.4) | 1.7 | − 6.0; 9.5 | 5.7 (3.3) | 2.7 | − 6.7; 12.1 |
| Knee | ||||||
| Knee flexion ROM | 2.2 (0.9) | 0.4 | − 3.1; 3.9 | 3.0 (1.5) | 1.4 | − 3.3; 6.0 |
| Knee flexion ROM, stance (K1) | 2.8 (1.3) | 1.6 | − 1.9; 5.1 | 1.9 (1.7) | 0.7 | − 2.0; 3.4 |
| Knee flexion ROM, stance to swing (K3) | 2.5 (1.3) | − 1.7 | − 5.1; 1.6 | 2.6 (1.3) | − 1.5 | − 5.5; 2.5 |
| Knee extension ROM, MSt to TSt (K2) | 2.5 (1.3) | − 2.1 | − 4.9; 0.7 | 3.4 (1.8) | − 3.0 | − 6.7; 0.6 |
| Knee flexion, IC | 7.8 (1.9) | 5.8 | − 2.2; 13.7 | 4.8 (3.3) | 2.2 | − 6.3; 10.7 |
| Peak knee flexion, stance | 15.3 (7.5) | 14.2 | − 0.4; 28.8 | 11.0 (7.5) | 9.8 | − 5.5; 25.0 |
| Peak knee extension, stance | 9.3 (2.8) | − 8.3 | − 1.1; − 15.5 | 5.3 (4.0) | − 4.0 | − 12.5; 4.6 |
| Peak knee flexion, swing | 8.5 (2.5) | 7.6 | 1.2; 14.1 | 5.4 (3.6) | 4.1 | − 4.1; 12.3 |
| Ankle | ||||||
| Ankle dorsiflexion ROM, stance (A1) | 2.7 (1.1) | 2.0 | − 1,1; 5.2 | 2.7 (0.7) | 1.7 | − 1.5; 4.9 |
| Ankle dorsiflexion ROM, swing | 2.3 (1.8) | 1.1 | − 3.3; 5.4 | 2.4 (1.0) | 1.1 | − 2.3; 4.6 |
| Ankle plantarflexion ROM, push off (A2) | 2.6 (1.7) | 0.5 | − 4.8; 5.8 | 3.4 (1.6) | 2.2 | − 2.7; 7.1 |
| Ankle dorsiflexion, IC | 3.6 (1.7) | − 2.8 | − 7.3; 1.7 | 5.5 (1.8) | − 4.6 | − 10.8; 1.6 |
| Ankle plantarflexion, TO | 4.1 (1.3) | 1.9 | − 4.1; 7.9 | 6.1 (3.3) | 5.1 | − 1.7; 11.8 |
| Peak ankle plantarflexion | 4.3 (2.1) | 1.1 | − 6.9; 9.2 | 5.4 (2.9) | 4.6 | − 2.7; 11.9 |
A1 corresponding to A1 power phase of ankle, A2 corresponding to A2 power phase of ankle, CI confidence interval, H3 corresponding to H3 power phase of hip, HR heel rise, IC initial contact, ICC intraclass correlation coefficient, K1 corresponding to K1 power phase of knee, K2 corresponding to K2 power phase of knee, K3 corresponding to K3 power phase of knee, LoA limits of agreement, LR loading response, MSt mid-stance, PLHIV people living with HIV-1-infection, RMSE root-mean-square error, SNP HIV-seronegative participants
Fig. 2Relative reliability of gait parameters and kinematics measured by inertial measurement units. Error bars indicate 95% confidence intervals
Absolute reliability (measurement error) of gait parameters measured by inertial measurement units
| Parameter | SEM | %SEM | Upper 95% CL | SEM | %SEM | Upper 95% CL |
|---|---|---|---|---|---|---|
| SNP | PLHIV | |||||
| Spatial parameters | ||||||
| Step length (cm) | 4.01 | 6.09 | 4.81 | 4.33 | 6.82 | 5.20 |
| Normalized step length | 0.04 | 5.20 | 0.05 | 0.05 | 6.98 | 0.06 |
| Stride length (cm) | 3.20 | 2.46 | 3.84 | 4.03 | 3.23 | 4.84 |
| Normalized stride length | 0.04 | 2.65 | 0.05 | 0.05 | 3.56 | 0.06 |
| Temporal parameters | ||||||
| Cadence (steps/min) | 8.31 | 7.08 | 9.97 | 9.67 | 8.82 | 11.60 |
| Normalized cadence | 2.45 | 7.04 | 2.94 | 2.83 | 8.57 | 3.40 |
| Stance time (s) | 0.06 | 9.78 | 0.07 | 0.03 | 4.48 | 0.04 |
| Step time (s) | 0.04 | 7.70 | 0.05 | 0.04 | 7.22 | 0.05 |
| Single support time (s) | 0.03 | 7.14 | 0.04 | 0.03 | 6.91 | 0.04 |
| Double support time (s) | 0.03 | 15.23 | 0.04 | 0.03 | 12.77 | 0.04 |
| Temporophasic parameters | ||||||
| Stance percentage (%GC) | 1.97 | 3.31 | 2.36 | 1.60 | 2.63 | 1.92 |
| Single support percentage (%GC) | 2.56 | 6.34 | 3.07 | 2.49 | 6.32 | 2.99 |
| Double support percentage (%GC) | 2.18 | 11.42 | 2.62 | 2.30 | 10.71 | 2.76 |
| Temporospatial parameters | ||||||
| Gait speed (m/s) | 0.02 | 1.58 | 0.02 | 0.02 | 1.75 | 0.02 |
| Normalized gait speed | 0.04 | 9.20 | 0.05 | 0.04 | 10.34 | 0.05 |
SEM 95% CL were calculated using a sample-and-trial-specific multiplying factor of 1.2 [19]
%SEM absolute percentage SEM, CL confidence limits of SEM, GC gait cycle, PLHIV people living with HIV-1 infection, SEM standard error of measurement, SNP HIV-seronegative participants
Absolute reliability (measurement error) of kinematic angles measured by inertial measurement units
| Angle/ROM (degrees) | SNP | PLHIV | ||
|---|---|---|---|---|
| SEM | Upper 95% CL | SEM | Upper 95% CL | |
| Pelvis | ||||
| Pelvis tilt ROM | 0.7 | 0.8 | 0.8 | 1.0 |
| Peak pelvis anterior tilt | 1.1 | 1.3 | 1.2 | 1.4 |
| Pelvis obliquity ROM | 0.9 | 1.1 | 1.1 | 1.3 |
| Pelvis rotation ROM | 2.1 | 2.5 | 1.8 | 2.2 |
| Pelvis rotation, IC | 5.2 | 6.2 | 3.7 | 4.4 |
| Hip | ||||
| Hip flexion ROM | 2.4 | 2.9 | 2.1 | 2.5 |
| Hip flexion ROM, LR | 1.7 | 2.0 | 2.6 | 3.1 |
| Hip flexion ROM, PS to IS (H3) | 2.3 | 2.8 | 2.0 | 2.4 |
| Hip flexion, IC | 2.4 | 2.9 | 2.1 | 2.5 |
| Peak hip flexion, swing | 2.2 | 2.6 | 2.1 | 2.5 |
| Peak hip extension, stance | 1.8 | 2.2 | 2.4 | 2.9 |
| Hip abduction ROM, mid-stance | 2.6 | 3.1 | 2.0 | 2.4 |
| Hip adduction ROM, LR | 1.4 | 1.7 | 1.5 | 1.8 |
| Hip internal rotation ROM | 2.6 | 3.1 | 2.8 | 3.4 |
| Knee | ||||
| Knee flexion ROM | 1.4 | 1.7 | 2.2 | 2.6 |
| Knee flexion ROM, stance (K1) | 2.9 | 3.5 | 2.5 | 3.0 |
| Knee flexion ROM, stance to swing (K3) | 3.0 | 3.6 | 2.8 | 3.4 |
| Knee extension ROM, MSt to TSt (K2) | 1.9 | 2.3 | 2.4 | 2.9 |
| Knee flexion, IC | 3.0 | 3.6 | 3.2 | 3.8 |
| Peak knee flexion during stance, LR | 3.9 | 4.7 | 5.8 | 7.0 |
| Peak knee extension, stance | 2.9 | 3.5 | 3.1 | 3.7 |
| Peak knee flexion, swing | 2.0 | 2.4 | 2.9 | 3.5 |
| Ankle | ||||
| Ankle dorsiflexion ROM, stance (A1) | 2.0 | 2.4 | 1.9 | 2.3 |
| Ankle dorsiflexion ROM, swing | 2.9 | 3.5 | 3.3 | 4.0 |
| Ankle plantarflexion ROM, push off (A2) | 2.2 | 2.6 | 3.7 | 4.4 |
| Ankle dorsiflexion, IC | 2.0 | 2.4 | 2.1 | 2.5 |
| Ankle plantarflexion, TO | 5.2 | 6.2 | 4.4 | 5.3 |
| Peak ankle plantarflexion | 4.1 | 4.9 | 4.4 | 5.3 |
A1 corresponding to A1 power phase of ankle, A2 corresponding to A2 power phase of ankle, H3 corresponding to H3 power phase of hip, HR heel rise, IC initial contact, K1 corresponding to K1 power phase of knee, K2 corresponding to K2 power phase of knee, K3 corresponding to K3 power phase of knee, LR loading response, MSt mid-stance, PLHIV people living with HIV-1 infection, ROM range of motion, SEM standard error of measurement, SNP HIV-seronegative participants, TO toe-off, TSt terminal stance
Fig. 3Comparative gait traces for people living with HIV (PLHIV) and HIV-seronegative participants (SNP). Sagittal plane kinematic traces are shown as measured by optical motion capture (OMC) (a–d) and inertial measurement units (IMUs) (e–h). The graphs illustrate the mean (solid lines) ± standard deviation (shaded areas bounded by dashed lines) estimated by each system for each group. Note similarities in magnitude and direction of differences between PLHIV and SNP as observed by each system
Gait parameter differences between people with and without HIV as measured by the respective systems
| Parameter | Mean difference | 95% CI | Mean difference | 95% CI | ||
|---|---|---|---|---|---|---|
| IMU | OMC | |||||
| Spatial parameters | ||||||
| Step length (cm) | 2.29 | − 2.92; 7.50 | 0.36 | 2.60 | − 1.9; 7.1 | 0.24 |
| Normalized step length | 0.05 | − 0.03; 0.13 | 0.19 | 0.10 | 0.0; 0.1 | 0.09 |
| Stride length (cm) | 5.31 | − 5.11; 15.73 | 0.29 | 5.62 | − 3.52; 14.76 | 0.21 |
| Normalized stride length | 0.11 | − 0.04; 0.26 | 0.15 | 0.11 | − 0.01; 0.24 | 0.08 |
| Temporal parameters | ||||||
| Cadence (steps/min) | 7.71 | − 2.11; 17.54 | 0.11 | 7.34 | − 2.41; 17.09 | 0.13 |
| Stance time (s) | − 0.06 | − 0.11; 0.00 | 0.04* | − 0.06 | − 0.11; 0.00 | 0.04* |
| Step time (s) | − 0.04 | − 0.09; 0.01 | 0.12 | − 0.04 | − 0.09; 0.01 | 0.11 |
| Single support time (s) | − 0.02 | − 0.06; 0.03 | 0.41 | − 0.02 | − 0.06; 0.02 | 0.37 |
| Double support time (s) | − 0.04 | − 0.07; − 0.01 | 0.01* | − 0.04 | − 0.06; − 0.02 | < 0.01* |
| Temporophasic parameters | ||||||
| Stance time (%GC) | − 1.41 | − 2.90; 0.09 | 0.06 | − 1.29 | − 2.13; − 0.45 | 0.01* |
| Single support time (%GC) | 0.99 | − 0.65; 2.62 | 0.22 | 1.06 | 0.20; 1.92 | 0.02* |
| Double support time (%GC) | − 2.39 | − 5.34; 0.56 | 0.10 | − 2.35 | − 3.97; − 0.73 | 0.01* |
| Temporospatial parameters | ||||||
| Gait speed (m/s) | 0.12 | − 0.02; 0.26 | 0.09 | 0.13 | 0.00; 0.27 | 0.06 |
| Normalized gait speed | 0.05 | 0.00; 0.10 | 0.06 | 0.05 | 0.00; 0.10 | 0.03* |
Asterisks indicate statistically significant differences between participant groups
%GC percentage of gait cycle, IMU inertial measurement units, OMC optical motion capture
Kinematic differences between people with and without HIV as measured by the respective systems
| Kinematic angle | Mean difference | 95% CI | Mean difference | 95% CI | ||
|---|---|---|---|---|---|---|
| IMU | OMC | |||||
| Ankle | ||||||
| Ankle dorsiflexion ROM during stance (A1) | − 0.3° | − 4.1°; 3.5° | 0.87 | − 0.6° | − 4.7°; 3.5° | 0.76 |
| Ankle dorsiflexion ROM during swing | 6.4°* | − 1.2°; 13.9° | 0.09 | 6.4°* | − 0.6°; 13.4° | 0.07 |
| Ankle plantarflexion ROM during push off (A2) | 4.3° | − 2.3°; 11.0° | 0.18 | 6.1°* | − 0.3°; 12.4° | 0.06 |
| Ankle dorsiflexion angle at IC | − 1.5° | − 4.8°; 1.9° | 0.36 | − 1.2° | − 4.2°; 1.8° | 0.42 |
| Ankle plantarflexion angle at TO | 4.6° | − 2.1°; 11.4° | 0.16 | 0.0°; 11.3° | 0.05 | |
| Peak ankle plantarflexion during GC | 5.9°* | − 1.6°; 13.4° | 0.11 | 7.2°* | 0.2°; 14.3° | 0.05 |
| Knee | ||||||
| Knee flexion ROM during GC | 2.6° | − 3.3°; 8.4° | 0.36 | 3.6° | − 1.4°; 8.6° | 0.15 |
| Knee flexion ROM during stance (K1) | 0.3° | − 4.7°; 5.4° | 0.90 | − 0.6° | − 5.4°; 4.3° | 0.80 |
| Knee flexion ROM from stance to swing (K3) | 3.9° | 0.0°; 7.8° | 0.05 | 4.1° | 0.2°; 8.1° | 0.04* |
| Knee extension ROM, MSt to TSt (K2) | 2.7° | − 2.3°; 7.8° | 0.26 | 1.8° | − 3.5°; 7.1° | 0.47 |
| Knee flexion at IC | 0.0° | − 5.3°; 5.3° | 1.00 | 0.1° | − 4.1°; 4.4° | 0.95 |
| Peak knee flexion during stance, LR | − 1.1° | − 6.8°; 4.6° | 0.69 | − 1.8° | − 7.3°; 3.7° | 0.49 |
| Peak knee extension during stance | 1.0° | − 3.4°; 5.5° | 0.63 | 1.7° | − 1.6°; 5.0° | 0.30 |
| Peak knee flexion during swing | 1.9° | − 0.8°; 4.6° | 0.16 | 2.0° | − 0.5°; 4.6° | 0.11 |
| Hip | ||||||
| Hip flexion ROM during GC | 4.6° | 0.2°; 9.0° | 0.04* | 2.6° | − 1.5°; 6.7° | 0.19 |
| Hip flexion ROM during LR | − 1.2° | − 3.5°; 1.1° | 0.28 | − 0.4° | − 2.7°; 1.8° | 0.69 |
| Hip flexion ROM, PS to IS (H3) | 0.4° | − 3.1°; 3.8° | 0.83 | − 1.2° | − 3.4°; 1.1° | 0.28 |
| Hip flexion angle at IC | − 0.66° | − 10.4°; 9.3° | 0.90 | − 0.8° | − 9.3°; 7.8° | 0.85 |
| Peak hip flexion during swing | 0.7° | − 8.4°; 9.7° | 0.87 | − 0.8° | − 8.4°; 6.9° | 0.84 |
| Peak hip extension during stance | 3.7° | − 5.2°; 12.7° | 0.39 | 3.3° | − 4.8°; 11.5° | 0.397 |
| Hip abduction ROM during mid-stance | − 0.4° | − 3.4°; 2.6° | 0.79 | 2.8° | 0.9°; 4.8° | 0.01* |
| Hip adduction ROM during loading response | 1.6° | − 1.2°; 4.4° | 0.24 | 1.3° | − 0.7°; 3.2° | 0.18 |
| Hip internal rotation ROM during GC | 1.1° | − 3.1°; 5.3° | 0.59 | 2.1° | − 1.9°; 6.0° | 0.28 |
| Pelvis | ||||||
| Pelvis tilt ROM during GC | 0.5° | − 1.9°; 3.0° | 0.65 | 0.7° | − 0.4°; 1.9° | 0.20 |
| Peak pelvis anterior tilt during GC | − 1.6° | − 9.6°; 6.3° | 0.66 | − 1.4° | − 8.6°; 5.8° | 0.69 |
| Pelvis obliquity ROM during GC | 1.2° | − 2.0°; 4.4° | 0.44 | 3.5° | − 0.4°; 7.5° | 0.08 |
| Pelvis rotation ROM during GC | 0.6° | − 6.2°; 7.4° | 0.85 | 1.4° | − 4.0°; 6.8° | 0.60 |
| Pelvis rotation at IC | 0.5° | − 2.8°; 3.9° | 0.74 | 0.7° | − 2.9°; 4.3° | 0.68 |
Asterisks indicate clinically and/or statistically significant differences between participant groups
A1 corresponding to A1 power phase of ankle, A2 corresponding to A2 power phase of ankle, H3 corresponding to H3 power phase of hip, HR heel rise, IC initial contact, K1 corresponding to K1 power phase of knee, K2 corresponding to K2 power phase of knee, K3 corresponding to K3 power phase of knee, LR loading response, MSt mid-stance, PLHIV people living with HIV-1 infection, ROM range of motion, SEM standard error of measurement, SNP HIV-seronegative participants, TO toe-off, TSt terminal stance
Sample description
| Characteristic | SNP ( | PLHIV ( | |
|---|---|---|---|
| Age in years, mean (SD) | 28.84 (8.11) | 36.61 (9.44) | 0.10 |
| Female sex, | 6 (75) | 4 (50) | 0.30 |
| Height (m), mean (SD) | 1.59 (0.09) | 1.64 (0.08) | 0.20 |
| Weight (kg), mean (SD) | 49.51 (11.24) | 57.23 (9.99) | 0.17 |
| BMI (kg/m2), mean (SD) | 19.54 (3.03) | 21.19 (3.50) | 0.33 |
| Leg length (cm), mean (SD) | 84.72 (5.52) | 85.86 (4.40) | 0.65 |
| Most recent CD4+ T-cell count (cells/µL), mean (SD) | – | 558.25 (181.80) | – |
| Detectable viral load (> 50 cp/mL), | – | 6 (75) | – |
| Years since HIV diagnosis, | – | ||
| < 2 years | – | 4 (50) | – |
| 2–5 years | – | 2 (25) | – |
| 5–15 years | – | 1 (12.5) | – |
| > 15 years | – | 1 (12.5) | – |
| On ART, | – | 6 (75) | – |
| ART duration in weeks, median (IQR) | – | 71.50 (16.00–465.00) | – |
BMI body mass index, ART antiretroviral therapy, PLHIV people living with HIV-1 infection, SNP HIV-seronegative participants
Fig. 4Marker and inertial measurement unit (IMU) placement